Tag Archives: PFE

Pfizer (PFE) Shares Bought by D.A. Davidson & CO.

D.A. Davidson & CO. grew its stake in Pfizer (NYSE:PFE) by 3.7% during the fourth quarter, HoldingsChannel reports. The firm owned 402,659 shares of the biopharmaceutical company’s stock after buying an additional 14,417 shares during the quarter. D.A. Davidson & CO.’s holdings in Pfizer were worth $14,584,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of PFE. Investment Centers of America Inc. raised its holdings in Pfizer by 2.3% in the 3rd quarter. Investment Centers of America Inc. now owns 195,611 shares of the biopharmaceutical company’s stock valued at $6,990,000 after buying an additional 4,472 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH raised its holdings in Pfizer by 437.9% in the 3rd quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 773,073 shares of the biopharmaceutical company’s stock valued at $27,607,000 after buying an additional 629,361 shares during the last quarter. SG Americas Securities LLC raised its holdings in Pfizer by 3,116.6% in the 4th quarter. SG Americas Securities LLC now owns 1,186,121 shares of the biopharmaceutical company’s stock valued at $42,961,000 after buying an additional 1,149,246 shares during the last quarter. Oldfield Partners LLP raised its holdings in Pfizer by 33.1% in the 4th quarter. Oldfield Partners LLP now owns 109,850 shares of the biopharmaceutical company’s stock valued at $3,979,000 after buying an additional 27,300 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund raised its holdings in Pfizer by 1.2% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 1,652,936 shares of the biopharmaceutical company’s stock valued at $59,010,000 after buying an additional 19,989 shares during the last quarter. Institutional investors own 71.57% of the company’s stock.

Get Pfizer alerts:

In related news, CEO Ian C. Read sold 132,312 shares of Pfizer stock in a transaction on Tuesday, May 1st. The shares were sold at an average price of $36.01, for a total value of $4,764,555.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director W Don Cornwell sold 1,758 shares of Pfizer stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $36.79, for a total transaction of $64,676.82. Following the completion of the sale, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $36,790. The disclosure for this sale can be found here. Insiders sold a total of 380,349 shares of company stock valued at $13,829,340 in the last quarter. 0.06% of the stock is currently owned by company insiders.

NYSE:PFE opened at $34.93 on Tuesday. The firm has a market capitalization of $207.40 billion, a PE ratio of 13.18, a P/E/G ratio of 1.73 and a beta of 0.89. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.35 and a quick ratio of 1.10. Pfizer has a twelve month low of $31.67 and a twelve month high of $39.43.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.03. The company had revenue of $12.91 billion during the quarter, compared to analyst estimates of $13.14 billion. Pfizer had a net margin of 41.29% and a return on equity of 25.96%. Pfizer’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.69 EPS. analysts forecast that Pfizer will post 2.95 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, May 11th will be paid a $0.34 dividend. The ex-dividend date is Thursday, May 10th. This represents a $1.36 annualized dividend and a dividend yield of 3.89%. Pfizer’s dividend payout ratio is currently 51.32%.

A number of research analysts recently issued reports on the stock. BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, January 30th. SunTrust Banks restated a “hold” rating and set a $40.00 price target (up previously from $33.00) on shares of Pfizer in a report on Monday, January 29th. Morgan Stanley raised their price target on shares of Pfizer from $41.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. UBS set a $42.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, January 31st. Finally, Societe Generale set a $40.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Wednesday, January 31st. Three analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $39.57.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

In Your 60s? 3 Stocks You Should Consider Buying

Some might think investors in their 60s should steer clear of stocks. And that’s not entirely correct.

Sure, shifting some of your portfolio to less volatile investing alternatives like bonds makes sense. However, stocks should still be an important component of investment accounts for individuals in this age group. The big question, though, is: Which stocks to buy?

I think Alphabet (NASDAQ:GOOG) (NASDAQ:GOOGL), Iron Mountain (NYSE:IRM), and Pfizer (NYSE:PFE) are great picks for investors in their 60s. Here’s what makes these three stocks stand out.

Alphabet
You might be surprised for Google parent Alphabet to make the list since the stock doesn’t pay a dividend. But while it’s great to have solid dividend stocks in your portfolio (and we’ll get to two of them shortly), stocks of companies with strong moats and excellent growth prospects should be included as well. Alphabet checks off both of those boxes in a big way.

All of those ads you see on Google search engine, Gmail, Google Maps, Google Play, and YouTube generate most of Alphabet’s revenue. Do these revenue sources enjoy strong moats? Yep. The various Google websites claim a 63% search engine market share, higher than the share a decade ago despite well-funded competition. Alphabet continues to invest in research and development to make searches increasingly better. As a result, the company’s enormous cash flow should be pretty secure.

Alphabet uses the cash generated from its core businesses to invest in growth opportunities. The company lumps these opportunities into a business segment called “other bets.” Some of these other bets are already making plenty of money. Alphabet’s Nest home technology products, for example, generated $726 million in revenue last year. Others could be huge moneymakers down the road. I’d definitely put Waymo, Alphabet’s self-driving car technology company, in that category.

Although Alphabet is a gigantic company now, it’s a nimble giant. I think the stock has plenty of room for growth — mainly because it has plenty of ways to grow.

Iron Mountain
Now for a great dividend pick. Iron Mountain’s dividend currently yields over 7%. That’s a better income stream than most bonds. Because Iron Mountain is organized as a real estate investment trust (REIT), the company must distribute at least 90% of its taxable income to shareholders in the form of dividends. But how reliable are those dividends? Thanks to Iron Mountain’s business model, I’d say very reliable.

Iron Mountain is the world’s largest provider of records and data storage. The company has been in business for 67 years. It has 87.5 million square feet of storage space in more than 1,400 facilities. Iron Mountain has over 225,000 customers in 53 countries, including 95% of the Fortune 1000.

Those customers tend to stay with Iron Mountain, too. There’s no other company with the credentials that Iron Mountain has. Plus, it’s a huge headache to transfer records and data that are in storage to another vendor.

While Iron Mountain’s dividend is its main draw, the company has pretty good growth prospects as well. There are lots of growth opportunities in emerging markets. Iron Mountain has also expanded into the lucrative data-center business.

Pfizer
It’s hard to top Iron Mountain’s dividend yield. And Pfizer doesn’t. But the big pharma company does pay a dividend yielding nearly 4%. That’s certainly a level of income that few investors would turn down.

Pfizer’s dividend is also one you can depend on. The company recently paid out its 317th consecutive quarterly dividend. If you’re in your 60s, you’re at least 10 years younger than Pfizer’s dividend program.

I think Pfizer is also entering a period of solid growth. The pharmaceutical company has struggled somewhat over the last few years because of loss of exclusivity for several of its drugs. But Pfizer is steadily getting past that overhang with the help of fast-growing newer products like anticoagulant Eliquis and cancer drug Ibrance.

Pfizer also has its best drug pipeline in years. Between 2005 and 2010, the company rolled out only two blockbuster drugs. From 2011 through 2016, Pfizer launched five blockbusters. Thanks in large part to its extensive network of partners, Pfizer thinks over the next five years it will introduce up to 15 new drugs or new indications for existing drugs with the potential for annual sales of $1 billion or more.

Just a start
I really like Alphabet, Iron Mountain, and Pfizer — and not just for investors in their 60s. I’m years away from hitting my sixth decade, but I own two of these stocks myself. Keep in mind, though, that these three stocks are just a start. You’ll want to have more stocks in a balanced portfolio.

Alphabet, Iron Mountain, and Pfizer exemplify the kinds of stocks you should seek. Look for stocks with strong moats and solid growth prospects. Lean toward companies that pay reliable dividends with attractive yields. That should be a winning formula over time.

This article originally appeared on The Motley Fool.

Apple, McDonald’s, Pfizer and Other Dow Earnings Coming This Week

Most of the Dow Jones industrial index components have reported their latest quarterly reports, and overall the results have been solid. Yet the index is marginally lower than it was two weeks ago.

This week, five of the 30 Dow components are expected to share their results this week. The Dow has been subject to increased volatility since January, and some investors may have looked to the current earnings season to stabilize the index.

24/7 Wall St. has put together a preview of those Dow companies scheduled to report their quarterly results this week. Here, we have included the consensus earnings estimates from Thomson Reuters, as well as the stock price and trading history.

Also see our separate preview of some of the week’s other most anticipated earnings reports, including Alibaba, CVS and Tesla.

Be advised that the earnings and revenue estimates may change ahead of the formal reports, and some companies may change reporting dates as well.

McDonalds Corp. (NYSE: MCD) is set to report its most recent quarterly results first thing Monday morning. Analysts are looking for $1.67 in earnings per share (EPS) and $4.97 billion in revenue. Shares closed the week at $158.30, with a consensus price target of $185.54 and a 52-week trading range of $190.59 to $259.77.

Merck & Co. Inc. (NYSE: MRK) is expected to report its first-quarter results early Tuesday. The analysts consensus forecast is EPS of $1.00 on $10.10 billion in revenue. Shares were changing hands at $59.47 as last week came to a close. The consensus price target is $68.40, and the stock has a 52-week range of $52.83 to $66.41.

Pfizer Inc. (NYSE: PFE) will share its latest quarterly earnings before Tuesdays opening bell as well. The consensus estimates call for $0.75 in EPS and $13.15 billion in revenue. Shares ended last week at $37.00, in a 52-week range of $31.67 to $39.43. The consensus analyst target is $40.11.

Apple Inc. (NASDAQ: AAPL) is scheduled to share its quarterly report late on Tuesday. The consensus estimates are $2.69 in EPS on $60.98 billion in revenue. Shares were last seen at $162.32. The stock has a 52-week range of $142.20 to $183.50, and the consensus price target is $192.94.

And DowDuPont Inc. (NYSE: DWDP) is expected to report its most recent quarterly results before regular trading begins on Thursday. The consensus analyst estimates are $1.10 in EPS and revenue of $21.42 billion. Shares of DowDuPont were at $64.32 on Fridays close. The consensus price target is $82.80, and the 52-week range is $59.29 to $77.08.

ALSO READ: Alibaba, CVS, Tesla and Other Earnings to Watch For This Week

The 10 Best Stocks to Invest In Right Now

It’s a different market than it was at the end of January. Volatility has returned, even if it remains modest relative to historical levels. Big names like Procter & Gamble Co (NYSE:PG) and Walmart Inc (NYSE:WMT), among others, have seen precipitous share price declines after record highs.

It’s a choppier, more cautious, environment. That’s not a bad thing, however. After a basically uninterrupted post-election rally, several stocks have seen pullbacks that provide more attractive entry points. Others simply haven’t received their due credit from the market.

While there might be reasons for caution overall — higher interest rates, trade war concerns — more opportunities exist as well.

This more and more looks like a “stockpicker’s market.” For those stockpickers, here are 10 stocks to buy that look particularly attractive at the moment.

Editor’s Note: This story originally ran on March 15, 2018

10 Best Stocks to Invest In Right Now: Exxon Mobil xom stock Source: Shutterstock

I’m as surprised as anyone that Exxon Mobil Corporation (NYSE:XOM) makes this list. I’ve long been skeptical toward XOM. The internal hedge between upstream and downstream operations makes Exxon stock a surprisingly poor play on higher oil prices. Overall, it leads XOM to stay relatively rangebound — as it has been for basically a decade now.

But price matters. And XOM is at its lowest levels in more than two years after a steady decline since late January. With the dividend over 4% and a 16x forward P/E multiple, Exxon Mobil stock looks like a value play. Meanwhile, management is forecasting that earnings can double by 2025, adding a modest growth component to the story.

Obviously, there’s a risk that Exxon management is being too optimistic. Years of underperformance relative to peers like Chevron Corporation (NYSE:CVX) and even BP plc (ADR) (NYSE:BP) has eroded the market’s confidence. If Tesla Inc (NASDAQ:TSLA) can lead a true electric car revolution, that, too, could impact demand and pricing going forward.

At current levels, however, the market is pricing in close to zero chance of Exxon hitting its targets. And that’s why XOM is attractive right now. A continuation of the status quo still gives investors 4%+ income annually. Any improvements in production, or pricing, provide upside. At a two-year low, Exxon doesn’t have to be perfect to see upside in XOM stock.

10 Best Stocks to Invest In Right Now: Nathan’s Famous Nathan's Hot Dog Eating Contest 2017 Source: Flickr

In this market, recommending a restaurant owner — let alone a hot dog restaurant owner — might seem silly at best. But there’s a strong bull case for Nathan’s Famous, Inc. (NASDAQ:NATH) at the moment.

NATH, too, has seen a sharp pullback of late. The stock touched a 52-week (and all-time) high just over $100 in November. It’s since come down about 25%, though roughly one-sixth of the decline can be attributed to a $5 per share special dividend paid in December.

Yet the story hasn’t really changed all that much. Fiscal Q3 earnings in February were solid. The company’s agreement with John Morrell, who manufactures Nathan’s product for retail sale and Sam’s Club operations, offers huge margins, while revenue continues to grow. Foodservice sales similarly are increasing.

The restaurant business has been choppier. But it remains profitable. The mostly-franchised model there is similar to those of Domino’s Pizza, Inc. (NYSE:DPZ) and Yum! Brands, Inc. (NYSE:YUM), among others, all of whom are getting well above-market multiples.

All told, Nathan’s has an attractive licensing model, which leverages revenue growth across the operating businesses. And yet, at 13x EV/EBITDA, and 20x P/FCF, the stock trades at a significant discount to peers. NATH has stabilized over the past few weeks, and Q4 earnings in June could be a catalyst for upside. Investors would do well to buy NATH ahead of that report.

10 Best Stocks to Invest In Right Now: Bank of America 3 Reasons BAC Stock Has More Upside Source: Shutterstock

Bank of America Corp (NYSE:BAC) trades at its highest levels since the financial crisis, and has gained over 150% from July 2016 lows. Trading has been a bit choppier of late — no surprise for a macro-sensitive stock in this market — and there’s a case, perhaps, to wait for a better entry point.

But I’ve liked BAC stock for some time now, and as I wrote last month I don’t see any reason to back off yet. Earnings growth should be solid for the foreseeable future, given rising Fed rates and a strong economy.

BofA itself has executed nicely over the past few years. The company’s credit profile is solid and its stock has outperformed other big banks like Citigroup Inc (NYSE:C) and even JPMorgan Chase & Co. (NYSE:JPM). And tax reform and easing capital restrictions mean a big dividend hike could be on the way as well.

And despite the big run, it’s not as if BAC is expensive. The stock still trades at less than 11x 2019 EPS estimates. Unless the economy turns south quickly, that seems too cheap. So it looks like the big run in Bank of America stock isn’t over yet.

10 Best Stocks to Invest In Right Now: Nutrisystem Source: Nutrisystem

Nutrisystem Inc. (NASDAQ:NTRI) is another candidate to buy on a pullback. In a disappointing Q4 earnings release at the end of February, Nutrisystem disclosed a rough start to 2018. The beginning of the year is known as “diet season”, a key period for companies like Nutrisystem and  Weight Watchers International, Inc. (NYSE:WTW), as many customers look to act on New Year’s Resolutions.

But marketing missteps led to poor results from Nutrisystem. 2018 guidance now implies basically zero revenue growth — after analysts had projected a 13% increase for the full year.

Still, Nutrisystem is now priced almost as if growth is coming to an end for good. And I as argued at the time, that’s just too pessimistic. The average Street target price still is well above $40, implying over 30% upside. NTRI now trades at under 14x the midpoint of 2018 EPS guidance, and yields 3.5%.

The valuation implies that Nutrisystem management is wrong — that 2018’s deceleration is a permanent change. If Nutrisystem management is right — and they’ve earned some credibility in leading revenue and profit to soar over the past few years — then $29 is a far too cheap price for NTRI.

10 Best Stocks to Invest In Right Now: Roku Why There's a Lot of Volatility Coming for ROKU Stock Source: Shutterstock

Roku Inc (NASDAQ:ROKU) undoubtedly is the riskiest stock on this list. And there certainly is a case for caution. The company remains unprofitable on even an Adjusted EBITDA basis. A ~7x EV/revenue multiple isn’t cheap; it’s even higher considering that almost half of 2018 revenue will come from the player business, which is a ‘loss leader’ for advertising and platform revenue.

But management also detailed a really interesting future on the Q4 call. The company is looking to build a true content ecosystem — and from a subscriber standpoint, already has surpassed Charter Communications Inc (NASDAQ:CHTR) and trails only AT&T Inc. (NYSE:T) and Comcast Corporation (NASDAQ:CMCSA).

Again, this is a high-risk play — but it’s also a high-reward opportunity. Margins in the platform segment are very attractive, and should allow Roku to turn profitable relatively quickly. International markets remain largely untapped. There’s a case for waiting for a better entry point, or selling puts. But I like ROKU at these levels for the growth/high-risk portion of an investor’s portfolio.

10 Best Stocks to Invest In Right Now: Brunswick Source: Shutterstock

Brunswick Corporation (NYSE:BC) is due for a breakout. The boat, engine, and fitness equipment manufacturer is nearing resistance around $63 that’s held for close to a year now. Despite a boating sector that has roared of late, BC — the industry leader — has been mostly left out.

Over the last year, smaller manufacturers Marine Products Corp. (NYSE:MPX), Malibu Boats Inc (NASDAQ:MBUU), and MCBC Holdings Inc (NASDAQ:MCFT) have gained 51%, 71%, and 68%, respectively. BC, in contrast, has gained less than 2%. It actually trades at a discount to MBUU and MCFT — despite its leadership position and strong earnings growth of late.

Efforts to build out a fitness business have had mixed results, and may support some of the market’s skepticism toward the stock. But Brunswick now is spinning that business off, returning to be a boating pure-play.

Cyclical risk is worth noting, and there are questions as to whether millennials will have the same fervor for boating as their parents. But at 12x EPS, with earnings still growing double-digits, BC is easily worth those risks.

And if the stock finally can break through resistance, a breakout toward $70+ seems likely.

10 Best Stocks to Invest In Right Now: Pfizer 3 Reasons to Be Bullish on PFE Stock Source: Shutterstock

Few investors like the pharmaceutical space at this point — or even healthcare as a whole. But amidst that negativity, Pfizer Inc. (NYSE:PFE) looks forgotten.

This still is the most valuable drug manufacturer in the world (for now; it’s neck and neck with Novartis AG (ADR) (NYSE:NVS)). It trades at just 12x EPS, a multiple that suggests profits will stay basically flat in perpetuity. To top it off, PFE offers a 3.8% dividend yield.

Obviously, there are risks here. Drug pricing continues to be subject to political scrutiny (though the spotlight seems to have dimmed of late). Revenue growth has flattened out of late. But Pfizer still is growing earnings, with adjusted EPS rising 11% last year and guidance suggesting a similar increase this year. Tom Taulli last month cited three reasons to buy Pfizer stock – and I think he’s got it about right.

10 Best Stocks to Invest In Right Now: Valmont Industries Source: Shutterstocks

Valmont Industries, Inc. (NYSE:VMI) offers a diversified portfolio — and across the board, business has been relatively weak of late. The irrigation business has been hit by years of declining farm income. Support structures manufactured for utilities and highways have seen choppy demand due to uneven government spending. Mining weakness has had an impact on Valmont’s smaller businesses as well.

Valmont is a cyclical business where the cycles simply haven’t been much in the company’s favor. Yet that should start to change. 5G and increasing wireless usage should help the company’s business with cellular phone companies. Irrigation demand almost has to return at some point. And a possible infrastructure plan from the Trump Administration would benefit Valmont as well.

Concerns about the recently imposed tariffs on steel likely have hit VMI, and sent it back to support below $150. But many of Valmont’s contracts are ‘pass-through’, which limits the direct impact of those higher costs on the company itself. Despite uneven demand, EPS has been growing steadily, and should do so in 2018 as well.

And yet VMI trades at an attractive 16x multiple — a multiple that suggests Valmont is closer to the top of the cycle than the bottom. That seems unlikely to be the case, and as earnings grow and the multiple expands, VMI has a clear path to upside.

10 Best Stocks to Invest In Right Now: American Eagle Outfitters

Is It Worth Chasing the Rally in AEO Stock?investorplace.com/wp-content/uploads/2016/10/aeomsn-300×165.jpg 300w, investorplace.com/wp-content/uploads/2016/10/aeomsn-55×30.jpg 55w, investorplace.com/wp-content/uploads/2016/10/aeomsn-200×110.jpg 200w, investorplace.com/wp-content/uploads/2016/10/aeomsn-162×88.jpg 162w, investorplace.com/wp-content/uploads/2016/10/aeomsn-65×36.jpg 65w, investorplace.com/wp-content/uploads/2016/10/aeomsn-100×55.jpg 100w, investorplace.com/wp-content/uploads/2016/10/aeomsn-91×50.jpg 91w, investorplace.com/wp-content/uploads/2016/10/aeomsn-78×43.jpg 78w, investorplace.com/wp-content/uploads/2016/10/aeomsn-170×93.jpg 170w” sizes=”(max-width: 728px) 100vw,728px” />

American Eagle Outfitters (NYSE:AEO) is one of the, if not the, best stocks in retail — and that’s kind of the problem. Mall retailing, in particular, has been a very tough space over the past few years. And it’s not just the impact of Amazon.com, Inc. (NASDAQ:AMZN) and other online retailers. Traffic continues to decline, which pressures sales and has led to intense competition on price, hurting margins.

But American Eagle has survived rather well so far, keeping comps positive and earnings stable. And yet this stock, too, trades at around 12x EPS, backing out its net cash. And American Eagle has an ace in the hole: its aerie line, which continues to grow at a breakneck pace. aerie brand comparable sales rose 27% in fiscal 2017, on top of a 23% rise the year before.

The company’s bralettes and other products clearly are taking share from L Brands Inc (NYSE:LB) unit Victoria’s Secret. And the e-commerce growth in that business, and for American Eagle as a whole, suggests an ability to dodge the intense pressure on mall-based retailers.

In short, American Eagle isn’t going anywhere. There’s enough here to suggest American Eagle can eke out some growth, and a 2.6% dividend provides income in the meantime.

The stock already is recovering from a post-earnings sell-off last week, and should continue to do so. And longer-term, there’s still room for consistent growth, and more upside.

10 Best Stocks to Invest In Right Now: United Parcel Service Source: UPS

United Parcel Service, Inc. (NYSE:UPS) fell when the broad market did in February — and simply never recovered. A disappointing Q4 earnings report, in which investors saw signs of higher spending, drove some of the decline. But UPS stock wound up falling 22% in a matter of weeks — which looks like an unjustified sell-off.

UPS is going to have to spend to add capacity, and in this space too there’s the ever-present threat of Amazon. But UPS is an entrenched leader, along with rival FedEx Corporation (NYSE:FDX), and it at worst can co-exist with Amazon. E-commerce growth overall should continue to increase demand; there’s enough room for multiple players in the global market.

Meanwhile, the sell-off and benefits from tax reform mean that UPS now is trading at just 15x the midpoint of its guidance for 2018. And the stock yields a healthy 3.4%. Investors clearly see a risk that growth will decelerate, but UPS stock is priced as if that deceleration is guaranteed.

As of this writing, Vince Martin is long shares of Exxon Mobil and Nutrisystem. He has no positions in any other securities mentioned.

Compare Brokers